DOW JONES21,116.69-800.47 -3.65%
S&P 5002,483.12-101.47 -3.93%
NASDAQ7,443.90-256.20 -3.33%

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $43

JP Morgan maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $38 to $43.

Benzinga · 03/03/2020 13:40

JP Morgan maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $38 to $43.